237 related articles for article (PubMed ID: 20508163)
1. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.
Alvarez-Larrán A; Cervantes F; Pereira A; Arellano-Rodrigo E; Pérez-Andreu V; Hernández-Boluda JC; Ayats R; Salvador C; Muntañola A; Bellosillo B; Vicente V; Hernández-Nieto L; Burgaleta C; Xicoy B; Besses C
Blood; 2010 Aug; 116(8):1205-10; quiz 1387. PubMed ID: 20508163
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
[TBL] [Abstract][Full Text] [Related]
3. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
4. [Vascular complications of essential thrombocythemia].
Bellucci S
Bull Acad Natl Med; 2007 Mar; 191(3):519-30; discussion 530-3. PubMed ID: 18072651
[TBL] [Abstract][Full Text] [Related]
5. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.
Andriani A; Latagliata R; Anaclerico B; Spadea A; Rago A; Di Veroli A; Spirito F; Porrini R; De Muro M; Crescenzi Leonetti S; Villivà N; De Gregoris C; Montefusco E; Polverelli N; Santoro C; Breccia M; Cimino G; Majolino I; Mazzucconi MG; Vianelli N; Alimena G; Montanaro M; Palandri F
Am J Hematol; 2016 Mar; 91(3):318-21. PubMed ID: 26748894
[TBL] [Abstract][Full Text] [Related]
6. Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan.
Baba T; Hashimoto Y; Yasuda H; Araki M; Edahiro Y; Morishita S; Ochiai T; Shirane S; Ando J; Komatsu N
Hematology; 2022 Dec; 27(1):157-166. PubMed ID: 35068369
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Squizzato A; Romualdi E; Passamonti F; Middeldorp S
Cochrane Database Syst Rev; 2013 Apr; (4):CD006503. PubMed ID: 23633335
[TBL] [Abstract][Full Text] [Related]
8. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Randi ML; Rossi C; Fabris F; Girolami A
Clin Appl Thromb Hemost; 2000 Jan; 6(1):31-5. PubMed ID: 10726046
[TBL] [Abstract][Full Text] [Related]
9. Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia.
Kim KT; Sohn SI; Cho KH
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):913.e9-10. PubMed ID: 22305797
[TBL] [Abstract][Full Text] [Related]
10. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
11. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
12. Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study.
Alvarez-Larrán A; Pereira A; Arellano-Rodrigo E; Hernández-Boluda JC; Cervantes F; Besses C
Br J Haematol; 2013 Jun; 161(6):865-71. PubMed ID: 23577924
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
15. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
Carobbio A; Thiele J; Passamonti F; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Vannucchi AM; Antonioli E; Gisslinger H; Buxhofer-Ausch V; Finazzi G; Gangat N; Tefferi A; Barbui T
Blood; 2011 Jun; 117(22):5857-9. PubMed ID: 21490340
[TBL] [Abstract][Full Text] [Related]
17. Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service.
Navarro LM; Trufelli DC; Bonito DR; Del Giglio A; Bollmann PW
Rev Assoc Med Bras (1992); 2016 Oct; 62(7):647-651. PubMed ID: 27925044
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Squizzato A; Romualdi E; Middeldorp S
Cochrane Database Syst Rev; 2008 Apr; (2):CD006503. PubMed ID: 18425953
[TBL] [Abstract][Full Text] [Related]
19. Essential thrombocythemia in young adults.
McIntyre KJ; Hoagland HC; Silverstein MN; Petitt RM
Mayo Clin Proc; 1991 Feb; 66(2):149-54. PubMed ID: 1994135
[TBL] [Abstract][Full Text] [Related]
20. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.
Alvarez-Larrán A; Cervantes F; Bellosillo B; Giralt M; Juliá A; Hernández-Boluda JC; Bosch A; Hernández-Nieto L; Clapés V; Burgaleta C; Salvador C; Arellano-Rodrigo E; Colomer D; Besses C
Leukemia; 2007 Jun; 21(6):1218-23. PubMed ID: 17519959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
